Quantum BioPharma Lawsuit Against Major Banks Featured in CTV Investigation on Market Manipulation

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) has been featured in the second part of CTV News' investigative program W5's three-part series examining the company's allegations of stock spoofing tied to its $700 million lawsuit against CIBC and RBC. The segment, reported by award-winning journalist Jon Woodward, highlights Quantum BioPharma's claims of widespread market manipulation and its impact on the company's efforts to advance Lucid-MS, a potential multiple-sclerosis treatment.

CEO Zeeshan Saeed and Co-Executive Chair Anthony Durkacz reiterated their concerns about the alleged activity during the W5 segment, noting that Canadian exchange data cited in the lawsuit points to millions of purportedly illegal orders originating from bank platforms. The company maintains that this alleged market manipulation has significantly affected its stock price and ability to raise capital for developing its pharmaceutical treatments.

Quantum BioPharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., the company is focused on the research and development of its lead compound, Lucid-MS, a patented new chemical entity shown to prevent and reverse myelin degradation in preclinical models.

The company also retains ownership of 20.11% of Unbuzzd Wellness Inc. as of March 31, 2025, and receives royalty payments from sales of unbuzzd(TM) products. Quantum BioPharma maintains a portfolio of strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc., which represents loans secured by residential or commercial property.

This news story is important because it highlights potential vulnerabilities in financial markets that could impact innovative companies developing treatments for serious medical conditions. Market manipulation allegations against major financial institutions raise questions about market integrity and the challenges faced by biotech companies in securing funding for critical medical research. The case could have broader implications for how financial markets regulate trading practices and protect emerging companies from potentially manipulative activities.

For investors and industry observers, the W5 investigation brings attention to the complex relationship between financial markets and biotech innovation. The outcome of Quantum BioPharma's lawsuit could influence regulatory approaches to market manipulation and affect how small to mid-cap companies navigate capital markets while developing potentially life-changing medical treatments. The latest news and updates relating to QNTM are available in the company's newsroom at https://ibn.fm/QNTM.